Real-life analysis of neoadjuvant therapy-associated benefits for pathological complete response and survival in early breast cancer patients - role of trastuzumab in HER2+ BC and platinum in TNBC

Title	Real-life analysis of neoadjuvant therapy-associated benefits for pathological complete response and survival in early breast cancer patients - role of trastuzumab in HER2+ BC and platinum in TNBC
Authors	Wei-Pang Chung, Chun-Ting Yang, Shuen-Ru Yang, Ching-Yen Su, Hsin-Wei Su, Shang-Yun Liu, Huang-Tz Ou
Magazine	Frontiers in Oncology
Date	01/24/2023
DOI	10.3389/fonc.2022.1022994
Introduction	Neoadjuvant therapy aims to achieve a pathological complete response (pCR) for enhanced overall survival (OS) in early breast cancer (eBC) patients, particularly those with HER2-positive (HER2+) and triple-negative breast cancer (TNBC) subtypes. Despite its benefits, large-scale real-world data on the effects of trastuzumab-based therapy for HER2+ and platinum-based therapy for TNBC are limited. This study utilised the Taiwan Cancer Registry and National Health Insurance Research Database to assess the clinical outcomes for patients with clinically lymph-node-positive (LN+) HER2+ and TNBC. Logistic regression and Cox proportional hazards models were used to evaluate the adjusted odds ratios (aOR) for achieving pCR and adjusted hazard ratios (aHR) for OS. Results indicated that trastuzumab significantly increased the pCR rates by 3.87-fold in HER2+ patients and provided OS benefits for those achieving pCR. Conversely, platinum therapy in TNBC patients increased pCR rates by 1.6-fold but did not enhance OS. These findings highlight the potential of trastuzumab in improving outcomes for HER2+ eBC patients and suggest the need for novel therapies for TNBC.
Quote	Wei-Pang Chung, Chun-Ting Yang and Shuen-Ru Yang et al. Real-life analysis of neoadjuvant-therapy-associated benefits for pathological complete response and survival in early breast cancer patients - role of trastuzumab in HER2+ BC and platinum in TNBC. Front Oncol. 2023. DOI: 10.3389/fonc.2022.1022994
Element	Platinum (Pt)
Industry	Pharmaceutical Industry